Premium
Comparative effectiveness of bevacizumab plus cisplatin‐based chemotherapy versus pemetrexed plus cisplatin treatment in East Asian non‐squamous non‐small cell lung cancer patients applying real‐life outcomes
Author(s) -
CHANG GeeChen,
AHN MyungJu,
WRIGHT Elaine,
KIM Heung Tae,
KIM JooHang,
KANG Jin Hyoung,
KIM SangWe,
SHERMAN Steven,
WALZER Stefan
Publication year - 2011
Publication title -
asia‐pacific journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 29
eISSN - 1743-7563
pISSN - 1743-7555
DOI - 10.1111/j.1743-7563.2011.01400.x
Subject(s) - pemetrexed , cisplatin , bevacizumab , medicine , oncology , lung cancer , chemotherapy
Aim: To indirectly compare real‐life clinical effectiveness of bevacizumab + cisplatin‐based therapy from the Safety of Avastin in Lung (SAiL) phase IV clinical trial with published evidence from the phase III clinical trial for pemetrexed + cisplatin among East Asian patients with non‐squamous metastatic or recurrent non‐small cell lung cancer (NSCLC). Methods: Survival outcomes were compared between subgroups of East Asian patients receiving treatments of either bevacizumab + cisplatin‐based chemotherapy or pemetrexed + cisplatin using a matching‐adjusted indirect comparison approach. Patient‐level data were used to derive a new group with similar characteristics compared to those reported in a phase III clinical trial evaluating pemetrexed + cisplatin therapy. Exclusions to the SAiL data included those with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 2, those with mixed cell histology, non‐East Asians and those who did not receive cisplatin‐based chemotherapy. In total 1000 samples of the pre‐matched analysis set of the SAiL data were selected that resulted in equal distributions of the ECOG PS and gender matching variables selected and evaluated for a progression‐free survival (PFS) outcome. Results: Median PFS was longer for patients treated with bevacizumab‐based therapy (7.4 months; 95% confidence interval [CI]: 6.7–8.2) versus pemetrexed + cisplatin (6.4 months; 95% CI N/A) among non‐squamous East Asian NSCLC patients. Conclusion: The results suggest that East Asian non‐squamous NSCLC patients treated with bevacizumab‐based therapy have a trend toward improved PFS outcomes compared to those treated with pemetrexed + cisplatin, even after adjusting for differences between the two trial groups.